Entity
  • Kinoxis Therapeutics Pty Ltd

    Created in 2017
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    1,868
  • Activities

  • Technologies

  • Entity types

  • Location

    Melbourne VIC 3000, Australia

    Melbourne

    Australia

  • Employees

    Scale: 2-10

    Estimated: 16

  • Engaged corporates

    1
    1 1
  • Added in Motherbase

    11 months, 3 weeks ago
Description
  • Value proposition

    Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney. Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.

    Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and has completed a Phase I clinical study. The company is also exploring other indications for KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.

    Kinoxis’ second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder) social anxiety disorder, dementia (including Alzheimer’s disease), and schizophrenia.

  • Kinoxis Therapeutics - Social Neuroscience Guided Therapeutics

    Developing novel therapeutics for social dysfunction and substance use disorders.

  • https://kinoxistherapeutics.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceutical, Pharmaceutical Manufacturing, Animal Health
Boehringer Ingelheim
Pharmaceutical, Pharmaceutical Manufacturing, Animal Health
Other

10 Oct 2024


Similar entities
Loading...
Loading...
Social network dynamics